A Prescription Drug User Fee Act target date of June 23, 2025 has been set for the application. The sBLA is supported by data from the randomized, open-label phase 3 CheckMate 8HW trial ...

In the PD-L1 ≥ 1% group, the median treatment duration was 17.7, 23.6, and 6.2 months in 5-year survivors treated with nivolumab plus ipilimumab, nivolumab, and chemotherapy, respectively (Table 1), ...

Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

There are estimated to be 13 distinct hereditary renal cell carcinoma (RCC) syndromes, each of which The response-based addition of ipilimumab to nivolumab in the treatment of advanced RCC resulted in ...

The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved median ...

Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to ipilimumab prolonged survival for patients with advanced melanoma. Nivolumab ...

Please provide your email address to receive an email when new articles are posted on . Nivolumab significantly improved RFS for advanced melanoma compared with ipilimumab after 9 years of follow-up.

The researchers reported that nivolumab and the combination regimen were active in SCLC patients and resulted in responses that lasted longer than many other investigational agents. Ten percent of ...

SAN FRANCISCO -- Frontline dual immunotherapy significantly improved progression-free survival (PFS) versus chemotherapy in microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) ...

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for the treatment of adults and children aged 12 years ...

Nivolumab plus ipilimumab provided long-term improvements in progression-free and overall survival when compared to sunitinib in patients with intermediate- or poor-risk advanced renal cell carcinoma.

Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study ...